Abstract:Metastasis is the process through which cancer cells break away from a primary tumor, travel through the blood or lymph system, and form new tumors in distant tissues. One of the preferred sites for metastatic dissemination is the brain, affecting more than 20% of all cancer patients. This figure is increasing steadily due to improvements in treatments of primary tumors. Stereotactic radiosurgery (SRS) is one of the main treatment options for patients with a small or moderate number of brain metastases (BMs). A frequent adverse event of SRS is radiation necrosis (RN), an inflammatory condition caused by late normal tissue cell death. A major diagnostic problem is that RNs are difficult to distinguish from BM recurrences, due to their similarities on standard magnetic resonance images (MRIs). However, this distinction is key to choosing the best therapeutic approach since RNs resolve often without further interventions, while relapsing BMs may require open brain surgery. Recent research has shown that RNs have a faster growth dynamics than recurrent BMs, providing a way to differentiate the two entities, but no mechanistic explanation has been provided for those observations. In this study, computational frameworks were developed based on mathematical models of increasing complexity, providing mechanistic explanations for the differential growth dynamics of BMs relapse versus RN events and explaining the observed clinical phenomenology. Simulated tumor relapses were found to have growth exponents substantially smaller than the group in which there was inflammation due to damage induced by SRS to normal brain tissue adjacent to the BMs, thus leading to RN. ROC curves with the synthetic data had an optimal threshold that maximized the sensitivity and specificity values for a growth exponent β * = 1.05, very close to that observed in patient datasets. After treatment of brain metastases with radiation therapy, a fraction of patients experience tumor recurrences and others display radiation necrosis (RN). Clinical data shows that the growth of RNs is faster, as measured by the growth exponent, than that of recurrent brain metastases. This reflects the inflammatory nature of the former, and provides a method to distinguish RN in the clinics from relapsing metastatic lesions. A simple mathematical model for the inflammatory response and a more sophisticate discrete stochastic simulator with many biological details were been developed to provide a mechanistic explanation of the differential dynamics of tumor growth versus inflammatory responses after stereotactic radiation surgery of metastatic brain lesions.

Surgery of enlarging lesions after stereotactic radiosurgery for brain metastases in patients with non‐small cell lung cancer with oncogenic driver mutations frequently reveals radiation necrosis: case series and review

Expanding the Spectrum of Radiation Necrosis after Stereotactic Radiosurgery (SRS) for Intracranial Metastases from Lung Cancer

Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma

Incidence of radionecrosis in single-fraction radiosurgery compared with fractionated radiotherapy in the treatment of brain metastasis

Management of Brain Metastases in Tyrosine Kinase Inhibitor-Treated Epidermal Growth Factor Receptor-Mutant Non-Small-cell Lung Cancer from the Perspective of Long-Term Radiation Brain Damage: A Multi-Institutional Retrospective Analysis.

Investigation of the risk factors in the development of radionecrosis in patients with brain metastases undergoing stereotactic radiotherapy

Response of treatment-naive brain metastases to stereotactic radiosurgery

154 Elucidating the Immune Landscape of Radiation Necrosis Through Single Cell Analysis of Recurrent Brain Lesions in Patients After Stereotactic Radio Surgery

Nineteen-Month Immunity to Adverse Radiation Effects Following 5-Fraction Re-radiosurgery With 43.6 Gy for Local Progression After Prior 3-Fraction Radiosurgery for Brain Metastasis From Pan-Negative Lung Adenocarcinoma

Updated risk models demonstrate low risk of symptomatic radionecrosis following stereotactic radiosurgery for brain metastases

Tyrosine Kinase Inhibitor Resistance Increased the Risk of Cerebral Radiation Necrosis After Stereotactic Radiosurgery in Brain Metastases of Non-small-Cell Lung Cancer: A Multi-Institutional Retrospective Case-Control Study

Local recurrence and survival following stereotactic radiosurgery for brain metastases from small cell lung cancer

LOCL-11 EGFR-MUTATED NON-SMALL CELL LUNG CANCER (NSCLC) LEPTOMENINGEAL DISEASE (LMD) IN A LARGE STEREOTACTIC RADIOSURGERY PATIENT COHORT: INCIDENCE AND OUTCOME

Clinical Outcomes and Targeted Genomic Analysis of Renal Cell Carcinoma Brain Metastases Treated with Stereotactic Radiosurgery

Adverse radiation effect and freedom from progression following repeat stereotactic radiosurgery for brain metastases

Single versus multiple fraction stereotactic radiosurgery for medium-sized brain metastases (4-14 cc in volume): reducing or fractionating the radiosurgery dose?

Radiation necrosis after radiation therapy treatment of brain metastases: A computational approach

Local Control Failure After Five-Fraction Stereotactic Radiosurgery Alone for Symptomatic Brain Metastasis From Squamous Cell Lung Carcinoma Despite 43 Gy to Gross Tumor Margin With Internal Steep Dose Increase and Tumor Shrinkage During Irradiation

Radt-45. Integration Of Functional Magnetic Resonance Imaging Into Stereotactic Radiosurgery Planning To Reduce Symptomatic Radiation Necrosis

Management of brain metastases from large cell neuroendocrine carcinoma of the lung: improved outcomes with radiosurgery

Risk of leptomeningeal carcinomatosis in patients with brain metastases treated with stereotactic radiosurgery